Crestone Announces Positive Data from Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
Primary endpoint met with high rates of clinical cure at day 12 Very low rates of recurrence...
Read More
Press Releases
Publication of Data on the Novel Antibiotic CRS0540
Announcement Regarding CRS0540: Crestone, Inc. and Praedicare Inc. Announce the Publication of...
Read More
Crestone, Inc. joins the Antimicrobials Working Group
June 8, 2021 – Announcement: Crestone, Inc. joins the Antimicrobials Working Group to Combat...
Read More
First Patient Enrolled in Phase 2 Clinical Trial + QIDP & Fast Track
June 7, 2021 – Announcement: Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial...
Read More
Funding Secured for Development Through Phase 1: CRS0540
July 1, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Development Through...
Read More
Grant Received from State of Colorado Advanced Industries Accelerator
May 29, 2020 – Announcement: Crestone, Inc. receives $250,000 Grant from State of Colorado...
Read More
NIH Funding Secured for Preclinical Development of CRS3123
Apr 27, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Preclinical Development...
Read More
Funding: Preclinical Development of Novel Antibiotic for NTM Infection
CFF Funding Secured Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of...
Read More
NIH Funding Secured for Phase 2 Clinical Trial of CRS3123
Sep 12, 2019 – Announcement: Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial...
Read More
Other News
Presentations at the 9th AMR Conference and at ICDS 2024
Crestone had the opportunity to showcase its innovative research at the 9th AMR Conference in Basel, Switzerland, and ICDS 2024 in Bled, Slovenia.
Become a Part of Our Projects
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor or a team member.
Inquiries
Have a question or comment? Follow the link below to contact us about general inquiries.
Careers
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Investors
If you're interested in becoming an investor to help fund our research and development, contact us today.